The paediatric eye tumour retinoblastoma is initiated by inactivation of RB1, a tumour suppressor on chromosome 13q. In addition to RB1 loss, many retinoblastomas show other genetic alterations including gains on chromosomes 6p21-pter and 1q31-q32. Recently, the minimal region of gains on chromosome 6 was narrowed to band p22. We examined genomic gains and expression changes in primary retinoblastomas to identify potential target genes in 6p22. Quantitative multiplex PCR detected copy numbers X3 in 25 (33%) tumours and no gains in 31 of 76 (40%) tumours. The remaining 20 (26%) samples showed gains only at some loci, most often including E2F3 and DEK in 6p22.3. Analysis of RNA from 21 primary retinoblastomas showed that expression levels of these and some other genes in 6p22 correspond to DNA gains. However, KIF 13A, a reported candidate oncogene on 6p, was expressed at low levels or absent. Clinical manifestation of tumours with gains at all 6p22 loci was distinct in that distribution of age at diagnosis was markedly shifted to older age compared to tumours with no or partial gains. In summary, our results suggest that DEK and E2F3 are potential targets of 6p gains in retinoblastoma.
Introduction
Retinoblastoma (Rb) is a malignant childhood tumour of the retina with an incidence of 1 in 13 500-25 000 newborns (Vogel, 1979) . Mutations resulting in loss of function of both alleles of the RB1 gene, a tumour suppressor gene located on 13q14, are a prerequisite for the development of this tumour (Friend et al., 1986) . Approximately 60% of affected children develop retinoblastoma in one eye only (unilateral retinoblastoma), and the remaining 40% of children develop retinoblastomas in both eyes. In most children with unilateral retinoblastoma, both RB1 mutations occur in somatic cells, while in the majority of patients with bilateral retinoblastoma, one of the mutant RB1 alleles originates from a de novo mutation in the germ line in one of the parents or is transmitted from a mutation-carrying parent.
The RB1 gene encodes a nuclear phosphoprotein, p110, which is expressed in many cell types. A wellcharacterized function of this protein is to control the transition into the S phase of the cell cycle depending on regulatory input (Mittnacht, 2005) . However, additional roles have emerged (Classon and Harlow, 2002; Mittnacht, 2005) . Mutations that result in disruption of this regulatory pathway are frequent in many human cancers. However, in most of these cancers, additional genetic alterations are required for tumorigenesis. It is reasonable to assume that for the development of retinoblastoma, genetic alterations other than the two mutations that result in inactivation of the RB1 gene play a role (Gallie et al., 1999) . This hypothesis is supported by the results of classical cytogenetic analysis and, more recently, comparative genomic hybridization (CGH) studies. Cytogenetic analyses have revealed recurrent genomic alterations in retinoblastoma, the most frequent being gains on 6p and 1q, and losses of 16q (for review, see Horsthemke, 1992) . Specifically, chromosome 6p gains have been detected in approximately 60% of retinoblastomas (Squire et al., 1984 (Squire et al., , 1985 . They are often present as an isochromosome 6p (i6p) and preferentially identified in histologically undifferentiated tumours with unfavourable prognosis (Cano et al., 1994) . Gallie et al. (1999) have proposed that a third mutation, M3, is required to interrupt signals normally inducing apoptosis in cells lacking normal RB1 function and that a gene on 6p may be the target of the M3 event.
Recently, the minimal region of chromosomal imbalance in retinoblastoma was mapped to chromosome band 6p22, corresponding to a 12 Mb region containing approximately 40 known genes (Chen et al., 2001 ; http:// www.ncbi.nih.gov/mapview/maps.cgi). Further analyses of genomic gains within this region have indicated that the KIF 13A gene, which encodes a kinesin-like motor protein, is the target of 6p gains (Chen et al., 2002) . To test whether inhibition of KIF 13A expression affects proliferation, two retinoblastoma cell lines, Y79 and RB 409, were treated with antisense oligonucleotides. Cell proliferation was moderately reduced in the treated cells (Chen et al., 2002) . Some members of the kinesin gene family play roles in the regulation of cell division (mitotic kinesins), and alteration of this function has been linked to cancer (Sakowicz et al., 2004) . In the case of the KIF 13A gene, however, phylogenetic evidence suggests that the encoded product is involved in intracellular transport (Nakagawa et al., 1997) , which is a role that has not been linked to cancer. Nevertheless, an as yet unknown alternative function of this gene might contribute to the inhibition of apoptosis or enhance tumour progression in other ways.
The aim of the present study was to identify genes on chromosome 6p22 that are important for the progression of retinoblastoma. We have determined the pattern of copy number changes of loci in 6p22 and have examined global RNA expression by DNA oligo array hybridization. To detect whether alterations of 6p22 are associated with distinct biologic behaviour, we have also tested if tumours with 6p gains show a different clinical manifestation.
Results

Localization of DNA copy number gains on 6p22
Quantitative multiplex PCR (QM-PCR) was used to identify gains at 13 loci on chromosome 6p22 and at two neighbouring genes in tumour DNA (Table 1, Figure 1) . In 76 primary retinoblastomas tested, we distinguished three patterns of copy number changes. Tumours from 31 (40%) patients showed no gain at any of the 6p loci investigated (no gain group, median ¼ 1.04/interquartil range (IQR) ¼ [0.98;1.10]/max. ¼ 1.25). In 25 (33%) tumours, all 6p loci had gains to levels of three or more copies (complete gain group, 2.11/[1.79;2.70]/4.69). This pattern of gains is consistent with the presence of a 6p isochromosome, which is a typical finding in retinoblastoma (Squire et al., 1984) . In the remaining 20 (26%) retinoblastomas, copy number gains were detected only at less than 90% of the 6p22 loci tested (partial gain group, 1.45/[1.17;1.45]/2.01). Copy number changes in most of these tumours were restricted to loci in 6p22, while the HLA-A gene and the JMJ gene, which are located in 6p21.3 and 6p23, respectively, had normal copy numbers (Figure 1 ). Gains within 6p22 most frequently included the E2F3 and DEK genes. The minimum region of gains defined by increased copy numbers at these loci did not include KIF 13A. In addition to primary tumours, we analysed DNA from retinoblastoma cell lines WERI-RB1, Y-79, RBL-30, RB247C3, RB383 and RB355. All these cell lines showed 6p22 gains but there was some variation of copy number changes at individual loci (Figure 1 ). WERI-RB1, RB355, RB383, RBL-30 and RB247C3 showed four or more copies for most of 6p loci, while Y79 only had three copies. In the uveal melanoma MEL 202 cell line, which was included as a control because it is known to have trisomy 6 (Nareyeck et al., submitted), values for all loci on chromosome 6 corresponded to copy numbers of 3 (1.51/[1.43;1.59]/1.63).
Comparison of QM-PCR data with results from CGH
CGH was performed in 68 of the 76 retinoblastoma samples investigated by QM-PCR (Table 2) . With CGH, genomic gains on 6p were detected in 32/68 tumours (47%). In 25 of them, the entire short arm of chromosome 6 was amplified. Seven tumours had partial gains in 6p and in two of them gains were not present in 6p22. QM-PCR identified increased copy numbers in all but one tumour that showed 6p22 gains in CGH. Of 36 tumours that showed no 6p22 gains in CGH, 13 were found to have increased copy numbers when analysed by QM-PCR. This reflects the superior sensitivity of QM-PCR for the detection of gains with low increase of copy number or narrow physical extent (Chen et al., 2002) .
Expression of amplified genes located in 6p22
Expression analysis was performed in 21 primary retinoblastomas, one retinoblastoma cell line (WERI-RB1) and for RNA from normal retina using an Affymetrix U133A Chip (Affymetrix, Santa Clara, CA, USA). Of the >12 000 genes tested by this array, 12 genes are located in 6p22.3 (MIR, SCA1, CAP2, Figure 1 Synopsis of results of QM-PCR: relative copy numbers of 15 loci on 6p and two control loci (10q and 6q) were investigated in 76 primary retinoblastomas. In 31 tumours, normal copy numbers (white boxes) were found for all loci; 20 tumours showed partial gain with mostly three copies (grey boxes); and 25 tumours showed gain of all investigated loci with mostly four and more copies (black boxes). Six investigated cell lines presented with increased copy numbers for all investigated loci By comparing RNA expression levels of 6p22.3 genes between tumours with and without 6p gains, we identified five genes with elevated expression in tumours with gains: CAP2 (Wilcoxon P ¼ 0.0019), NUP 153 (P ¼ 0.0004), E2F3 (P ¼ 0.004), SOX4 (P ¼ 0.012) and TTRAP (P ¼ 0.0019) (Figure 2 ). Significance Analysis of Microarrays and Prediction Analysis of Microarrays software packages (SAM and PAM, respectively; Stanford University, CA, USA) were used to identify differentially regulated genes between tumours with copy number gains for all loci on 6p22 (n ¼ 10) and tumours (n ¼ 10) without gain at any of these loci. Using SAM, we found that expression of NUP 153, TTRAP and E2F3 is significantly higher in tumours with 6p22 gains (SAM q-values of 2.49, 2.49 and 4.9%, respectively). PAM, a bioinformatic tool that identifies genes that can be used as predictors for tumour classes, identified the same three genes as positive predictors of group affiliation. Other genes identified as differentially regulated or tumour class predictors are listed in Table 3 .
Correlation of 6p22 genomic gains with clinical data
We explored if our molecular findings in tumours are associated with aspects of clinical presentation in patients with isolated unilateral retinoblastoma (Table 4) . We found that the distribution of patient age at diagnosis was significantly different depending on the pattern of chromosome 6p gains (Figure 3 , Wilcoxon Po0.001). Tumours with complete gains at loci on 6p were diagnosed significantly later with a median age at diagnosis of 890 days compared to children whose tumours showed no or partial 6p gains (305 and 373 days, respectively). We did not find associations between the presence of chromosome 6p gains and tumour size, tumour calcification or of tumour necrosis, tumour invasion, or allele loss at the RB1 locus. Targets of chromosome 6p gains in retinoblastoma C Grasemann et al 
Discussion
Gains involving the short arm of chromosome 6p are a recurrent aberration in retinoblastoma. By CGH analysis, the minimum region was narrowed to chromosome band 6p22 (Mairal et al., 2000; Chen et al., 2001 Chen et al., , 2002 Herzog et al., 2001) . Using QM-PCR, we have identified gains within this region in 45/76 (60%) samples of These patients have bilateral retinoblastoma (n ¼ 5); all other patients (n ¼ 71) have unilateral retinoblastoma. Splice, point mutation that is predicted to disrupt regular splicing; methyl, hypermethylation of promoter of the RB1 gene; promoter, point mutation in the RB1 gene promoter; LOH, loss of constitutional heterozygosity at one or more STR loci in the RB1 Figure 2 RNA expression levels (log 10) of 10 genes on 6p22.3 and JMJ (6p23) and RFP (6p22.1). Differences between RNA expression levels in tumours with and without genetic gains on 6p (as defined by results of QM-PCR) were tested using the Wilcoxon test. Of the investigated genes, CAP2, NUP 153, E2F3, SOX4, TTRAP and RFP** showed significant higher RNA expression in response to increased copy numbers (*Po0.01, **Po0.001) Targets of chromosome 6p gains in retinoblastoma C Grasemann et al primary retinoblastomas, a percentage that is somewhat higher compared to studies based on CGH, which identified gains in 44-54% of retinoblastomas (Mairal et al., 2000; Chen et al., 2001 Chen et al., , 2002 Herzog et al., 2001 ).
As we also had CGH data from most of our samples, we could compare these data sets and found that QM-PCR detected gains in some samples that were not detected by CGH. Thus, QM-PCR seems to have a higher sensitivity that, however, comes at a price because if larger regions are to be analysed in detail, the number of PCR target segments has to be increased accordingly. We analysed several targets in 6p22.3 by QM-PCR and thus could narrow down the minimum region of gains. Several tumours with gains of loci in 6p22.3 had normal copy numbers of the JMJ locus, which is the most telomeric locus in 6p22.3 tested here, while in other tumours, copy numbers of RFP and HLA-A, two genes centromeric to the 6p22.3 region, were normal. Therefore, our data indicate that the minimal region of chromosomal imbalance in 6p22.3 is located between JMJ and RFP and includes the NUP 153, KIF 13A, TPMT, DEK, ID4, E2F3 and TTRAP genes. Copy number gains were most consistently identified in the region containing the DEK and E2F3 genes. Genomic gains that occur during progression of a tumour are thought to be selected for because of enhanced expression of oncogenes. Therefore, expression analysis can help to distinguish activated oncogenes from other genes that are merely coamplified because of their location next to an oncogene. The oligonucleotide microarray U133A that we used for expression analysis has probes for several genes from the 6q22.3 target region. We found that some of these genes are expressed at very low levels (SCA1, TPMT, ID4) or not expressed at all (MIR, KIF 13A, PRL). In a previous report, KIF 13A was singled out as the functional target of chromosome 6p gains (Chen et al., 2002) . Our findings do not support this role because in the retinoblastomas and cell lines analysed here, expression of KIF 13A was found to be very low or absent. The expression levels of CAP2, NUP 153, DEK, E2F3, SOX4 and TTRAP were correlated with the presence of 6p gains. Supervised analysis of global expression patterns by SAM and PAM algorithms identified NUP 153, TTRAP and E2F3 genes as significantly overexpressed in tumours with 6p gains. The PAM algorithm also identified CSK2B, a casein kinase responsible for phosphorylation of DEK (Kappes et al., 2004a) , as a positive predictor of classes. Joint analysis of data on genomic gains and expression helped to narrow down the list of candidate genes, but no single gene within the 6p amplified region was identified as the exclusive target.
Several tumour entities, including bladder cancer, ovarian adenocarcinomas, small cell lung cancer, gastroesophageal and uterine corpus carcinomas, osteosarcomas and malignant melanomas show gains in the chromosome 6p21-pter region that are comparable to those observed in retinoblastoma (Boonstra et al., 2003; Micci et al., 2003; Hoglund et al., 2004; Koon et al., 2004; Lau et al., 2004; Partheen et al., 2004) . The findings in osteosarcomas, malignant melanomas, small . It is conceivable that the 6p gains in these tumours may target the same pathways that are altered in retinoblastoma. Recently, DEK and E2F3, the two genes with most consistent gains in the retinoblastomas analysed here, were identified as potential targets of amplification in bladder cancer (Casas et al., 2003; Sitwala et al., 2003; Feber et al., 2004; Foster et al., 2004; Oeggerli et al., 2004) . DEK was first identified as part of a fusion protein with the CAN/NUP 214 nucleoporin, formed in a subtype of acute myeloid leukaemia (AML) through an 'in-frame' translocation of chromosomes 6 and 9 (von Lindern et al., 1992) . Biochemical studies point to an involvement of DEK in transcriptional regulation. DEK contains various functional domains, including a SAFBox (scaffold attachment factor, DNA-binding), several phosphorylation sites and a second DNA binding domain (DBD) in the C-terminal portion of the protein.
DNA binding to the second DBD is dependent on phosphorylation by CK2 (Kappes et al., 2004a, b) . DEK introduces positive supercoils to bound DNA, resulting in denser packing of chromatin. Thus, DNA binding by DEK can modify chromatin accessibility in a phosphorylation-dependent manner, and in this way, alter the pace of transcription. The second gene with consistent gains in retinoblastomas analysed here is E2F3, which, together with E2F1 and E2F2, belongs to a subclass of E2F factors that are thought to act as transcriptional activators of genes that are derepressed following transition through the RB1-dependent G1/S-phase cell cycle checkpoint (Saavedra et al., 2002) . In addition, E2F3 may contribute to tumour development and progression in other ways. Recently, it was demonstrated that E2F3 represses p14/ARF, which is an important tumour repressor in the p53 pathway. The E2F3b isoform associates with the ARF promoter, and is responsible for cell quiescence (Parisi et al., 2002; Ginsberg, 2004) . According to these data, overexpression of E2F3 could result in repression of the p53 pathway and thus promote tumour progression. Taken together, data on the normal functions of DEK and E2F3 and on their role in tumour biology support that genomic gains of these genes can be relevant for the biology of retinoblastoma. In recent years, it has been recognized that tumour promotion in consequence of genomic gains does not necessarily depend on the deregulation of only a single target gene. Data in several tumour entities have suggested that joint overexpression of several coamplified genes can confer a selective advantage (Reifenberger et al., 1994; Hui et al., 1997) . Experiments using cultured tumour cells may help to delimitate the specific contribution of individual genes. Available retinoblastoma cell lines are likely to be valid models for such analyses because we found that these cells have genomic gains on chromosome 6p22 that are similar to primary tumours. However, from our findings regarding the clinical behaviour of tumours with 6p22 gains, it is not clear what effects might be induced by experimental manipulation of expression of candidate 6p22 oncogenes in cell culture. We found a distinct association between the presence and pattern of 6p22 gains in primary retinoblastoma and clinical manifestation. Specifically, the distribution of age at diagnosis of primary tumours with complete gains was shifted to older age compared to the age distributions of tumours with no gains and tumours with partial gains. As partial gains often included DEK and E2F3, this suggests that gains of these two genes do not contribute to the mechanisms underlying different age at diagnosis of tumours with copy number changes on 6p. Alternatively, older age at presentation of tumours with complete gains of larger contiguous genomic intervals on 6p may be a consequence of chromosomal instability, which is a typical finding in retinoblastomas diagnosed in older children (Herzog et al., 2001; van der Wal et al., 2003) . It remains to be clarified what kind of selective advantage favours proliferation of tumour cells with gains of DEK and E2F3 and how to measure this effect in an experimental system. In summary, we were able to narrow the minimal region of gain on 6p to the band 6p22.3 using a panel of retinoblastomas and retinoblastoma cell lines. We present evidence here that several of the genes in this region, including the previously suggested target, KIF 13A, are unlikely to be oncogenes relevant for the progression of retinoblastoma. The integration of data from genomic gain analysis and expression analysis indicates that the DEK and E2F3 genes, which both have been previously suggested as targets of chromosome 6p gains in other tumour types, are promising candidates for further experimental studies.
Materials and methods
Samples of primary retinoblastoma, and DNA and RNA extraction
Tissue samples were obtained from retinoblastoma patients after enucleation and immediately frozen in liquid nitrogen. Informed consent was obtained from all patients or their parents. Simultaneous histology assessment confirmed >80% tumour tissue content in all samples. DNA was extracted from each tumour with standard protocols and was used for routine mutation analysis of the RB1 gene. The present study analysed 76 tumours, in all of which oncogenic RB1 gene mutations were identified. These tumours were from 71 and five patients with isolated unilateral and bilateral retinoblastoma, respectively. For RNA analysis, additional tumour tissue samples were obtained from 21 of these patients. Previously, we observed remarkably rapid RNA degradation in retinoblastoma samples. Therefore, special care was taken after enucleation to ensure that the time between enucleation and shock freezing in liquid nitrogen was as short as possible. Samples were stored at À801C until RNA extraction using the RNeasy Mini Protocol for isolation of RNA from animal tissues (Qiagen, Hilden, Germany). Samples were treated with DNase to remove genomic DNA contamination. In addition to primary retinoblastomas, we analysed DNA and RNA from Y-79, WERI-RB1, RB247C3, RB355, RB383 and RBL-30 were cultivated in DMEM supplemented with 15% fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 4 mM L-glutamine, 50 mM ethandiol and 10 mg/ml insulin at 371C, 15% CO 2 and 80% humidity.
Quantitative multiplex PCR
We adapted the QM-PCR methods published by Chen et al. (2002) to screen for gene amplification on the short arm of chromosome 6 (6p21.3-6p22.3). We analysed the dosage of 15 PCR products located on 6p22-23 and of two internal controls on chromosomes 6q and 10q (Table 1) . We included five sequence tagged sites (STSs) on 6p22 that had been investigated in previous studies (Chen et al., 2002) . It was necessary to new PCR primers specific for the KIF 13A gene and the control locus on chromosome 10q because the primers used in the original protocol contained homocopolymers that caused polymerase slippage and this results in additional bands in high-resolution gel electrophoresis. PCR primers for amplification of the loci were selected using the web-based primer 3 program (http//frodo.wi.mit.edu/cgi-bin/primer3/ primer3.cgi) or were taken from STS entries in the NCBI database (http://www.ncbi.nih.gov). One of each primer pair was labelled with 6-FAM fluorescent dye (Biomers, Ulm, Germany). Amplicon sizes ranged from 180 to 350 bp. QM-PCR was performed in three reaction sets each targeting four or five distinct loci. In addition, all multiplex sets included primers for amplification of DEK (two loci) and two control loci outside of chromosome 6p.
Reactions were performed in 12.5 ml total reaction volume containing 93.75 ng of template DNA, 2 mmol of each primer and 6.25 ml of 2 Â QIAGEN Multiplex PCR Master Mix (Qiagen, Hilden, Germany). Amplification was performed in a GeneAmp PCR system 9700 thermocycler (Applied Biosystems, Foster City, CA, USA). PCR conditions were as follows: 951C for 15 min initial activation step, 19 cycles of 941C for 30 s, 571C for 90 s and 721C for 90 s, with a final extension for 10 min at 721C. Each PCR included samples from five DNAs without copy number changes (constitutional DNA from normal individuals). DNA from a cell line known to have three copies of 6p (Mel202, kindly provided by G Anastassiou and M Zeschnigk) was used as a positive control. Prior to electrophoresis, 1 ml of the reaction product was added to 12.5 ml of deionized formamide and 1 ml of ROX GeneScan-500 fluorescent DNA size standard (Applied Biosystems, Foster City, CA, USA). Analyses were performed using an ABI 3100 automated capillary genetic analyser and GeneScan software (Applied Biosystems, Foster City, CA, USA). The Genotyper software (Applied Biosystems) was used to determine peak signal areas for each PCR product.
Calculation of relative copy number
For normalization of values, peak areas of each product within one QM-PCR were divided by the peak area of the control locus on chromosome 10q that was obtained in the same reaction. To determine the relative DNA copy number for each locus, normalized peak integrals were compared to the mean of the values obtained from normal control DNA: (PI tu1 / PI tu1 kr10)/(PI NP /PI NP kr10). Using this algorithm, a value of 1 is obtained for loci with a DNA copy number of 2.
Expression analysis
Because of the small size of the tissue samples, RNA yields were rather low. Therefore, biotinylated cRNA was prepared using two rounds of amplification of 250 ng total RNA as described previously (Baugh et al., 2001) . Amplification of mRNA was quantified by in vitro transcription with minor modifications. Fragmentation of cRNA, hybridization to HG-U133A oligonucleotide arrays (Affymetrix Inc., Santa Barbara, CA, USA), washing and staining as well as scanning in a GeneArray scanner (Agilent, Palo Alto, CA, USA) were performed according to the manufacturers' recommendations (Affymetrix protocols, Technical Manual). Signal intensities and decision calls for further analysis were determined using GeneChip Microarray Suite (MAS) 5.0 Software (Affymetrix Inc., Santa Barbara, CA, USA). Scaling across all probe sets of a given array to an average intensity of 1000 units compensated for variations in the amount and quality of cRNA samples and other experimental variables.
Signal intensities and detection calls of the analysed genes were determined in the absolute analysis. Prior to further statistical analyses, all average difference values and gene information were exported to Excel 2000. Signal intensities were normalized to signal intensities from normal retina for comparative analysis (Human Retina total RNA, BD Biosciences Clontech). The Wilcoxon test was used to test for genes differentially expressed between tumours with or without 6p gain. SAM (Stanford University, CA, USA) was used to identify genes that were consistently differentially expressed between classes of tumours (as defined by distinct patterns of DNA copy number in 6p22 regardless of the absolute RNA expression level). PAM (Stanford University, CA, USA) was used to detect genes best predicting class affiliations.
Reverse transcription and quantitative real time-PCR
Single-stranded cDNA was generated from 100 ng of total RNA from WERI-RB1 cells using random hexamers in a 20 ml reaction using the GeneAmp RNA PCR kit (Applied Biosystems). Quantitative real-time PCR was performed in a 20 ml reaction volume containing 40 ng of cDNA, 1 Â Assay on Demand TM Gene Expression Assay Mix and 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems) according to the manufacturer's instructions. Reactions were run and analysed on the ABI PRISM 7700 Sequence Detection System (Applied Biosystems).
Western blotting
WERI-RB1, Y-79 and RBL-30 cells were washed three times in PBS and lysed in ice-cold NP-40 buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% NP-40) containing protease inhibitors. Lysates were cleared by centrifugation, and aliquots containing 50 mg of total protein were separated on a NuPAGE BisTris gradient gel (4-12% polyacrylamide) and then semi-dry blotted on nitrocellulose. Blots were blocked with 5% BLOTTO in PBS and then incubated with the anti-DEK monoclonal antibody (Becton-Dickinson Biosciences) diluted 1 : 1000 for 16 h at 41C. After washing 3 Â for 10 min in PBS containing 0.02% Tween 20, blots were incubated with biotinylated anti-mouse Ig (DAKO) diluted 1 : 500, followed by streptavidin-biotin-horseradish peroxidase complex (Amersham) for 1 h at room temperature. Immunocomplexes were detected using the ECL plus kit (Amersham) and Kodak X-Omat X-ray film.
Statistical analysis of genetic findings and patient data
Detailed information on clinical presentation, treatment and follow-up of patients were obtained. A data warehouse software environment (Cognos Series 7.1, Cognos Incorporated) was used to link all clinical and molecular data and to set the stage for data mining, which was performed using the tools provided by the software environment. Statistical evaluation of the findings was performed using the JMP 5.1 software (SAS Institute) and its cluster analysis platform.
